Related Experiment Videos
Acute hepatitis induced by cyproterone acetate.
N Giordano1, P Nardi, C Santacroce
1Institute of Internal Medicine, University of Siena, Italy. Giordanon@unisi.it
The Annals of Pharmacotherapy
|September 28, 2001
Summary
This case highlights the risk of acute hepatitis from cyproterone acetate, a prostate cancer treatment. Early cessation and corticosteroid therapy led to rapid improvement, suggesting an idiosyncratic drug reaction.
Area of Science:
- Hepatology
- Pharmacology
- Oncology
Background:
- Cyproterone acetate is an antiandrogen used as adjuvant therapy for prostate cancer.
- While generally considered well-tolerated, severe hepatic reactions have been reported.
Observation:
- An 87-year-old man developed acute hepatitis during cyproterone acetate treatment for prostate cancer.
- Clinical diagnosis was supported by liver biopsy showing acute cholestatic hepatitis.
- Discontinuation of cyproterone acetate and initiation of corticosteroids resulted in rapid clinical improvement.
Findings:
- Hepatotoxicity from cyproterone acetate can manifest as acute hepatitis.
- This reaction is likely an idiosyncratic drug-induced liver injury.
- The mechanism may involve hepatomitogen action, increasing preneoplastic hepatocytes.
Implications:
- Clinicians should be vigilant for potential hepatotoxicity in patients receiving cyproterone acetate.
- Prompt recognition and management are crucial for favorable patient outcomes.
- Further research into the mechanisms of cyproterone acetate-induced liver injury is warranted.